Artiva Biotherapeutics, Inc. (ARTV) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Artiva Biotherapeutics, Inc.
Address
5505 Morehouse Drive
San Diego, CA 92121
United States of America (the)
Phone
858 267 4467
Website
Sector
Healthcare
Industry
Biotechnology
Employees
115
First IPO Date
July 19, 2024
Key Executives
| Name | Title | Pay | Year Born |
| Fred Aslan | CEO, Principal Financial & Accounting Officer and Director | 1.22M | 1975 |
| Gines Diego Miralles | President and Head of Research & Development | 55,000 | 1963 |
| Peter Flynn | Co-Founder & Strategic Advisor | 499,368 | 1974 |
| Christopher Horan | Chief Technical Operations Officer | 777,619 | 1967 |
| Jennifer Kinsbruner Bush | Chief Operating Officer | 839,214 | 1975 |
| Benjamin Dewees | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Andrew Cronauer | VP, General Counsel & Corporate Secretary | 0 | N/A |
| David Moriarty | Senior Vice President of Clinical Operations | 0 | N/A |
| Heather Raymon | Senior Vice President of Research & Early Development | 0 | 1965 |
| Nicholas Veomett | Vice President of Corporate Development | 0 | N/A |
Description
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
